The Senate Health, Education, Labor, and Pensions Committee convened a hearing to examine how increasing competition, particularly from generics and biosimilars, can lower prescription drug prices. Witnesses representing health policy, industry-aligned research, and consumer advocacy perspectives discussed regulatory barriers, market dynamics, and policy reforms needed to improve access to lower-cost medicines while maintaining incentives for innovation. Witnesses, Dr. Brian Miller,… (Colocho, April 17, 2026) #340B, #Affordable Care Act, #Drug Pricing, #Food and Drug Administration, #Generic Drugs, #Pharmacies, #Pharmacy Benefit Managers, #Prescription Drugs, #Transparency